Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genexol-PM plus atezolizumab in platinum-pretreated advanced urothelial carcinoma (Phase 2, Korea)
KCT0006077Phase 2Not yet recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel polymeric micelle, atezolizumab in transitional cell carcinoma (TCC), sponsored by Samyang Biopharmaceuticals Corporation. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
paclitaxel polymeric micelleatezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on KCT0006077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006077.